CHANGE MY LOCATION
Business and Finance
Business News
Bush, allies seek to calm jittery investors- President Bush and the world's financial leaders staged repeated displays of unity Saturday to combat an unfolding credit crisis, hoping to calm investors whose panic has spread despite bold and accelerating government action.
- After consulting with Barack Obama, Democratic leaders are likely to call Congress back to work after the election in hopes of passing legislation that would include extended jobless benefits, money for food stamps and possibly a tax rebate, officials said Saturday.
- Hundreds of terrified Christian families have fled Mosul to escape extremist attacks that have increased despite months of U.S. and Iraqi military operations to secure the northern Iraqi city, political and religious officials said Saturday.
Rep. Lewis says McCain 'sowing seeds of hatred'- Rep. John Lewis, a Georgia Democrat and veteran of the civil rights movement, says the negative tone of the Republican presidential campaign reminds him of the hateful atmosphere that segregationist Gov. George Wallace fostered in Alabama in the 1960s.
- National forests and parks - long popular with Mexican marijuana-growing cartels - have become home to some of the most polluted pockets of wilderness in America because of the toxic chemicals needed to eke lucrative harvests from rocky mountainsides, federal officials said.
- For General Motors Corp. to acquire Chrysler LLC and all of its warts, GM would have to get desperately needed cash as part of the deal. Lots of it, according to industry analysts.
Lisa Marie Presley gives birth to twins- Lisa Marie Presley is a mom again. A publicist says the 40-year-old singer gave birth Tuesday to twin girls, whose names were not released. One baby weighed 5 pounds, 15 ounces and the other came in at 5 pounds and 2 ounces.
Kenya's elephants send text messages to rangers- The text message from the elephant flashed across Richard Lesowapir's screen: Kimani was heading for neighboring farms.
McCoy, No. 5 Longhorns upset No. 1 Sooners 45-35- The Texas Longhorns came into their annual showdown against the Oklahoma Sooners with a quarterback they could trust and a defense playing great under an aggressive new coordinator. Yet even after five solid wins, coach Mack Brown still wondered how good they were.
Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
SEATTLE
(Map)
-
Date Time Poster # Title
(Abstract#)
Sat., 8:00 AM 47D(8565) Phase I trial of yttrium 90
May 31 poster ibritumomab tiuxetan (90Y-RIT)
with autologous stem cell
transplantation (ASCT) in
patients with relapsed or
refractory B-cell non-
Hodgkin's lymphoma (NHL)
Sat., 8:00 AM 56E(8615) Yttrium-90 ibritumomab
May 31 poster tiuxetan combined with high-
dose BEAM chemotherapy and
autologous stem cell
transplantation for
relapsed/refractory B-cell
non-Hodgkin's lymphoma
Sun., 2:00 PM 20D(3075) Retrospective study of RIT
June 1 poster (radiolabelled immunotherapy)
with 90Y-IT (90Y-ibritumomab
tiuxetan) in relapsing FL
(follicular lymphoma) after
autologous (BM) bone marrow
transplant (ABMT)
Mon., 2:00 PM 32A(1063) Phase II trial of paclitaxel
June 2 poster poliglumex (PPX) with
capecitabine (C) for
metastatic breast cancer
(MBC).
For more information about the ASCO annual meeting, please refer to the conference Web site at http://www.asco.org/.
About Zevalin(R)
Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.
Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion- related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.
Patients and healthcare professionals can visit http://www.zevalin.com for more information.
About Cell Therapeutics, Inc.
Headquartered in
Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
http://www.CellTherapeutics.com/media.htm
Investors Contact:
Leah Grant
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
http://www.CellTherapeutics.com/investors.htm
Medical Information Contact:
T: 800.715.0944
E: info@askarm.com
|
|
More Business_and_Finance Releases
(ERJ): Embraer-Empresa Brasileira De Aeronautica S.A. Market Announcement
(MGPI): Union Local Accepts Labor Agreement Reinstatement Offer at MGP Ingredients, Inc. Atchison, Kan., Plant
